Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | SLC26A6 | Q9BXS9 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1299205 | 0.87 | KMT2A (0.44) | KMT2ACYP1A2TSHRCYP2C9CYP2C19 | |
| SCHEMBL1298563 | 0.77 | MAPK1 (0.57) | KMT2ACYP1A2TSHRCYP2C9CYP2C19 | |
| SCHEMBL21189606 | 0.73 | KMT2A (0.44) | KMT2ASMN1; SMN2KDM4EADORA2AADORA3 | |
| SCHEMBL29277998 | 0.71 | KMT2A (0.51) | KMT2ACYP1A2TSHRRAB9AKDM4E | |
| SCHEMBL1298704 | 0.71 | BAZ2B (0.40) | KMT2ACYP1A2CYP2C9CYP2C19NPC1 | |
| SCHEMBL7863456 | 0.70 | MAPK1 (0.59) | KMT2ACYP1A2CYP2C9CYP2C19NPC1 | |
| SCHEMBL352579 | 0.70 | CYP1A2 (0.54) | KMT2ACYP1A2TSHRNPC1RAB9A | |
| SCHEMBL15615316 | 0.70 | KMT2A (0.48) | KMT2ACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL24388944 | 0.68 | SMN1; SMN2 (0.58) | KMT2ACYP1A2CYP2C9CYP2C19RAB9A | |
| SCHEMBL17619378 | 0.67 | PDE4D (0.51) | KMT2ACYP1A2SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION | 2011-11-03 | — | — | US | disclosed |
| WO-2010002472-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269740-A1 | JAK KINASE MODULATING COMPOUNDS AND METHODS OF USE THEREOF | JAK2, JAK1, JAK3 | KMT2A 854/4885CYP1A2 3032/4885TSHR 2445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.